Loading
VRN110755 is an experimental small-molecule drug from Voronoi in phase 2 trials for non-small-cell lung cancer, aimed at EGFR.
VRN110755 is a small-molecule drug developed by Voronoi. Its target is EGFR (the sponsor names EGFR). The sponsor states: A highly selective oral EGFR inhibitor designed to target activating EGFR mutations and selected resistance mutations, including C797S, in EGFR-mutant NSCLC. ClinicalTrials.gov describes the intervention as: VRN110755 is an investigational highly selective oral EGFR inhibitor supplied as capsules for oral administration. The drug is designed to target activating EGFR mutations and selected resistance mutations, including C797S, in patients with. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer. The largest, NCT07699328, plans to enrol 315 participants with primary completion expected 2029-01-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A highly selective oral EGFR inhibitor designed to target activating EGFR mutations and selected resistance mutations, including C797S, in EGFR-mutant NSCLC. Connects to EGFR.
1.VRN110755 slips into a pocket on EGFR.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VRN110755" OR ABSTRACT:"VRN110755") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VRN110755, not a curated reading list.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR, Non-small-cell lung cancer and the tag pipeline.